SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strategies
Novo Nordisk has cut the price of Wegovy for the second time in South Africa, making obesity treatment pricing South Africa a key focus for improved patient access. The latest reductions, announced on 25 March 2026, lower the lowest injectable dose from 3,090 rand to 1,873 rand and the highest do...
Personalised Fertility Endometriosis Care in the UK
The updated NICE fertility guideline introduces a dedicated section for individuals with endometriosis who are struggling to conceive. This change formally recognises personalised fertility endometriosis as a distinct cause of infertility rather than grouping it under unexplained infertility.
Tarlatamab for Small Cell Lung Cancer Treatment
New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer
Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...